Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 469,414

Document Document Title
WO/2018/069855A1
The object of the invention is xanthohumol or its physiologically acceptable salt or a molecular complex or a metal complex for use in the treatment, prophylaxis or prevention of the haemorrhoidal disease or other diseases of the anal ar...  
WO/2018/071917A1
The disclosure provides methods of treating immunological conditions, e.g., allergy, by administration of berberine nanoparticles.  
WO/2018/071879A1
The presently described technology provides one or more compositions, preferably one or more immediate-release profile compositions, comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5- alpha-epoxy...  
WO/2018/069832A1
The present invention relates to a liquid composition for use in the treatment of gastroesophageal reflux. The composition of the present invention comprises a mixture which comprises or, alternatively, consists of a combination of Aloe ...  
WO/2018/069843A1
The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein ...  
WO/2018/069463A1
The present invention is directed to a compound for inhibiting (i) FGF-R kinase activity or (ii) a component of the FGFR kinase signaling pathway for use in the therapeutic or prophylactic treatment of viral infections as well as corresp...  
WO/2018/071283A1
The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.  
WO/2018/071531A1
The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, an...  
WO/2018/070819A1
The present invention relates to a composition comprising ciclesonide or a pharmaceutically acceptable salt thereof as an effective ingredient for suppressing the growth of cancer stem cells, a pharmaceutical composition comprising the s...  
WO/2018/069937A1
The present disclosure provides solid dispersions of trisodium sacubitril valsartan. Such solid dispersions may be useful in the manufacture of pharmaceutical dosage forms.  
WO/2018/071887A1
The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell grow...  
WO/2018/071655A1
Formulations containing pH-sensitive nanoparticles for the enteric delivery of therapeutic agents are provided. The nanoparticles include a pH-sensitive polymer that protects the therapeutic agent against degradation in the stomach and a...  
WO/2018/071701A1
In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need there...  
WO/2018/071740A1
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...  
WO/2018/068357A1
Disclosed are a compound as shown in formula I, or a pharmaceutically acceptable salt, a crystal form, a solvate thereof, wherein Z is selected from (II), (III), (IV) or (V); R1 is selected from H or (VI); R2 is selected from (VII) or (V...  
WO/2018/070953A1
The present invention relates to use of boron-doped nanohydroxyapatite (B- nHAp) nanocomposites -which increase effect of antibiotics against a wide spectrum of bacteria comprising multi-drug resistance (MDR) by exhibiting synergistic ef...  
WO/2018/068114A1
The present invention relates to a combination of the drugs curcumin (Cur), which is a natural polyphenol, and sodium diethyldithiocarbamate (DETC), or its precursor disulfiram (DS), which exhibits synergistically increased antimalarial ...  
WO/2018/068131A1
The present invention provides substituted hydroxystilbenes compounds of the general formula I that inhibit the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compounds can be ...  
WO/2018/069597A1
The present invention relates to a combination of a first antibiotic compound, Colistin, and a second antibiotic compound, selected from among Sulfadiazine and fusidic acid, for use in therapeutic treatment against pathogenic enterobacte...  
WO/2018/068090A1
The present invention relates generally to the field of glycanics and its application to the generation of glycoconjugates for therapeutic use. The present invention also relates to process for the preparation of glycoconjugates.  
WO/2018/070510A1
Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass reduction, even for the elderly and even without requiring exercise, by inducing myogenesis. Provided is a composition for treating...  
WO/2018/071343A1
Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventi...  
WO/2018/071526A1
This disclosure is directed to agonists of the apelin receptor (APJ) with heterocyclic cores and uses of such agonists.  
WO/2018/069763A1
The invention concerns a method for reducing or delaying the onset of irritation, discomfort, inflammation (acute or chronic), and/or an immune response at the ocular surface by topically administering a fluid comprising high molecular w...  
WO/2018/068566A1
An application of albiflorin or a pharmaceutically-acceptable salt thereof in production of products for regulating and improving the balance of the human intestinal flora. Albiflorin or a pharmaceutically-acceptable salt thereof, as a r...  
WO/2018/069732A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compo...  
WO/2018/069420A1
The present invention is related to new trioxolane derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to trioxolane derivatives useful for the preparation of ...  
WO/2018/071741A1
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...  
WO/2018/070406A1
The present invention provides a water-based adhesive patch which can stably contain only one of the optical isomers, S- and R-isomers, of a drug in a relatively high concentration over a long period and which has excellent tackiness and...  
WO/2018/071654A1
This document discloses a sustained release dosage form for oral administration of entecavir in a subject. Also disclosed is a method of treating hepatitis virus B infection.  
WO/2018/071581A1
The present invention provides oral pharmaceutical compositions comprising the release of at least two cannabinoids in the treatment of disorders or the symptoms thereof. A method of manufacture for their preparation and methods of use t...  
WO/2018/071282A1
The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib): (I) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.  
WO/2018/069536A1
The present invention provides TPCS2a, gemcitabine and optionally another cytotoxic agent, preferably cisplatin, for use in a method of treating a cholangiocarcinoma in a human patient comprising a photochemical internalization method. R...  
WO/2018/069468A1
The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors,and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic d...  
WO/2018/069126A1
The invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and car...  
WO/2018/069086A1
Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R=-C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1α and HIF-2α proteins...  
WO/2018/071381A1
Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measur...  
WO/2018/071656A1
Formulations and compositions for the treatment of migraine headaches, and in general, pain, include riboflavin, magnesium, feverfew and an amino acid, such as 5 -hydroxytryptophan (5-HTP).  
WO/2018/070874A1
The invention relates to the field of medicine. In particular, it relates to means and methods for reducing or avoiding the acquisition of antibiotic resistance. Provided is an agent capable of reducing the proton motive force (PMF) in b...  
WO/2018/069148A1
The invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and cardi...  
WO/2018/069833A1
The present invention relates to stable amorphous form of sacubitril valsartan trisodium complex and its solid dispersion compounds, processes for their preparation and pharmaceutical composition comprising the same. The present inventio...  
WO/2018/070069A1
The present invention provides a medicine comprising: a Toll-like receptor agonist; and LAG-3 protein, a variant thereof, or a derivative thereof.  
WO/2018/070711A2
The present invention relates to a pharmaceutical composition containing hyaluronic acid nanoparticles for preventing or treating an inflammatory disease and a metabolic disease and, more specifically, to a pharmaceutical composition for...  
WO/2018/069471A1
The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T ce...  
WO/2018/068296A1
Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a c...  
WO/2018/068769A1
Provided are the use of dihydroberberine type compounds and (±) -8-acetonyldihydroberberine type compounds in the preparation of products for preventing, alleviating and/or treating tumour diseases associated with the STAT3 signaling pa...  
WO/2018/069823A1
The invention relates to a single layer solid oral pharmaceutical composition comprising telmisartan or a pharmaceutically acceptable derivative thereof and at least one calcium channel blocker and process for preparation of the solid or...  
WO/2018/071233A1
The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-h exahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin- 8-yl)-butan-1-one, ...  
WO/2018/069936A1
An amorphous form of betrixaban maleate and process for the preparation of the same are disclosed. A solid dispersion of amorphous betrixaban maleate with pharmaceutically acceptable excipients and processes for the preparation of the sa...  
WO/2018/071329A1
The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for d...  

Matches 1 - 50 out of 469,414